Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy.

Tytuł:
Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy.
Autorzy:
Kralisch S; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.; IFB AdiposityDiseases, Leipzig University Medical Center, University of Leipzig, 04103 Leipzig, Germany.
Hoffmann A; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.
Estrada-Kunz J; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.
Stumvoll M; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.
Fasshauer M; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.; IFB AdiposityDiseases, Leipzig University Medical Center, University of Leipzig, 04103 Leipzig, Germany.; Department of Nutritional Sciences, University of Giessen, 35390 Gieβen, Germany.
Tönjes A; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.
Miehle K; Medical Department-Endocrinology, Nephrology, Rheumatology, University of Leipzig, 04103 Leipzig, Germany.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 29; Vol. 21 (19). Date of Electronic Publication: 2020 Sep 29.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Growth Differentiation Factor 15/*blood
Leptin/*blood
Lipodystrophy/*blood
Obesity/*blood
Sterol Regulatory Element Binding Protein 2/*genetics
Adipose Tissue/metabolism ; Animals ; Biomarkers/blood ; C-Reactive Protein/metabolism ; Female ; Gene Expression Regulation/genetics ; Glycated Hemoglobin/metabolism ; Growth Differentiation Factor 15/genetics ; Humans ; Insulin Resistance/genetics ; Lipodystrophy/genetics ; Lipodystrophy/pathology ; Male ; Mice ; Mice, Transgenic ; Middle Aged ; Obesity/genetics ; Obesity/pathology ; Triglycerides/blood
References:
Sci Rep. 2018 May 1;8(1):6789. (PMID: 29717162)
Int J Obes (Lond). 2018 Mar;42(3):561-571. (PMID: 29026214)
Eur J Endocrinol. 2010 May;162(5):913-7. (PMID: 20167682)
Hepatology. 2005 Apr;41(4):753-60. (PMID: 15791619)
Nature. 2017 Oct 12;550(7675):255-259. (PMID: 28953886)
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9. (PMID: 9326641)
J Clin Endocrinol Metab. 2011 Nov;96(11):3313-25. (PMID: 21865368)
Nature. 1999 Sep 2;401(6748):73-6. (PMID: 10485707)
Nat Med. 2007 Nov;13(11):1333-40. (PMID: 17982462)
Geriatr Gerontol Int. 2016 Mar;16 Suppl 1:17-29. (PMID: 27018280)
Trends Pharmacol Sci. 2015 Jul;36(7):461-70. (PMID: 26022934)
Biochem Biophys Res Commun. 2018 Apr 6;498(3):388-394. (PMID: 28847729)
Clin Endocrinol (Oxf). 2016 Jun;84(6):932-8. (PMID: 26572532)
Liver Int. 2018 Apr;38(4):695-705. (PMID: 28898507)
Physiol Res. 2009;58(1):1-7. (PMID: 19331512)
Nephrol Dial Transplant. 2012 Jan;27(1):70-5. (PMID: 21940482)
J Clin Endocrinol Metab. 2004 Sep;89(9):4258-63. (PMID: 15356018)
J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44. (PMID: 19174500)
Clin Chem. 2011 Feb;57(2):309-16. (PMID: 21164037)
Arthritis Rheum. 2007 Mar;56(3):753-64. (PMID: 17328047)
Eur J Endocrinol. 2012 Nov;167(5):671-8. (PMID: 22918303)
Cell Metab. 2019 Mar 5;29(3):707-718.e8. (PMID: 30639358)
J Biochem. 1997 Sep;122(3):622-6. (PMID: 9348093)
J Clin Endocrinol Metab. 2015 May;100(5):1802-10. (PMID: 25734254)
Circulation. 2007 Feb 27;115(8):962-71. (PMID: 17283261)
Nat Med. 2017 Oct;23(10):1215-1219. (PMID: 28846098)
Diabetologia. 2010 Jan;53(1):27-35. (PMID: 19727665)
PLoS One. 2015 Jul 24;10(7):e0133362. (PMID: 26207898)
Hypertension. 2009 Jul;54(1):106-12. (PMID: 19470878)
J Clin Endocrinol Metab. 2002 May;87(5):2395. (PMID: 11994394)
PLoS One. 2013;8(2):e55174. (PMID: 23468844)
Lancet. 2002 Jun 22;359(9324):2159-63. (PMID: 12090982)
Eur Heart J. 2016 Apr 21;37(16):1325-33. (PMID: 26417057)
Eur Heart J. 2007 Dec;28(23):2858-65. (PMID: 17977844)
Nutrients. 2014 Nov 18;6(11):5153-83. (PMID: 25412152)
Aging (Albany NY). 2014 Aug;6(8):690-704. (PMID: 25239873)
N Engl J Med. 2002 Feb 21;346(8):570-8. (PMID: 11856796)
J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. (PMID: 27710244)
Gut Liver. 2017 Mar 15;11(2):276-282. (PMID: 27728964)
Cancer Res. 2006 May 15;66(10):4983-6. (PMID: 16707416)
Circulation. 2011 May 17;123(19):2101-10. (PMID: 21536998)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Clin Chem. 2017 Jan;63(1):325-333. (PMID: 27811204)
Clin Endocrinol (Oxf). 2018 Jul;89(1):65-75. (PMID: 29722904)
Curr Opin Lipidol. 2009 Aug;20(4):300-8. (PMID: 19494770)
Nature. 2020 Feb;578(7795):444-448. (PMID: 31875646)
Gene. 1997 Dec 5;203(1):17-26. (PMID: 9426002)
Sci Transl Med. 2017 Oct 18;9(412):. (PMID: 29046435)
Aging Cell. 2010 Dec;9(6):1057-64. (PMID: 20854422)
Nat Med. 2017 Oct;23(10):1150-1157. (PMID: 28846097)
Biochim Biophys Acta. 2016 Jan;1862(1):113-20. (PMID: 26521149)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):240-5. (PMID: 20007767)
Biofactors. 2019 Jan;45(1):43-48. (PMID: 30496627)
J Leukoc Biol. 1999 Jan;65(1):2-5. (PMID: 9886240)
Genes Dev. 1998 Oct 15;12(20):3182-94. (PMID: 9784493)
Eur J Endocrinol. 2009 Sep;161(3):397-404. (PMID: 19515791)
Grant Information:
01EO1501 Bundesministerium für Bildung und Forschung; SFB 1052/2, C06 Deutsche Forschungsgemeinschaft
Contributed Indexing:
Keywords: GDF15; adipokine; insulin resistance; leptin; lipodystrophy; obesity; triglycerides
Substance Nomenclature:
0 (Biomarkers)
0 (GDF15 protein, human)
0 (Glycated Hemoglobin A)
0 (Growth Differentiation Factor 15)
0 (Leptin)
0 (Srebf2 protein, mouse)
0 (Sterol Regulatory Element Binding Protein 2)
0 (Triglycerides)
0 (hemoglobin A1c protein, human)
9007-41-4 (C-Reactive Protein)
Entry Date(s):
Date Created: 20201002 Date Completed: 20210225 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC7582938
DOI:
10.3390/ijms21197214
PMID:
33003626
Czasopismo naukowe
Objective . Similar to obesity, lipodystrophy (LD) causes adipose tissue dysfunction and severe metabolic complications. Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor β superfamily and is dysregulated in metabolic disease including obesity and diabetes mellitus. Circulating levels in LD and the impact of leptin treatment have not been investigated so far. Material and Methods . GDF15 serum levels were quantified in 60 LD patients without human immunodeficiency virus infection and 60 controls matched for age, gender, and body mass index. The impact of metreleptin treatment on circulating GDF15 was assessed in a subgroup of patients. GDF15 mRNA expression was determined in metabolic tissues of leptin-deficient lipodystrophic aP2-nSREBP1c-Tg mice, obese ob/ob mice, and control C57Bl6 mice. Results . Median GDF15 serum concentrations were significantly higher in LD patients (819 ng/L) as compared to the control group (415 ng/L) ( p < 0.001). In multiple linear regression analysis, an independent and positive association remained between GDF15 on one hand and age, patient group, hemoglobin A1c, triglycerides, and C-reactive protein on the other hand. Moreover, there was an independent negative association between GFD15 and estimated glomerular filtration rate. Circulating GDF15 was not significantly affected by metreleptin treatment in LD patients. Gdf15 was upregulated in leptin-deficient lipodystrophic mice as compared to controls. Moreover, Gdf15 mRNA expression was downregulated by leptin treatment in lipodystrophic and obese animals. Conclusions . Serum concentrations of GDF15 are elevated in LD patients and independently associated with markers of metabolic dysfunction. Gdf15 expression is higher in lipodystrophic mice and downregulated by leptin treatment.
Competing Interests: K.M. has consulted for Aegerion Pharmaceuticals. S.K., A.H., J.E.-K., M.S., M.F., and A.T. declare no conflict of interest.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies